Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 15/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512053 | 0.91 | P2RX7 (0.66) | P2RX7HPGDKDM4EP2RX3MAP2K7 | |
| SCHEMBL13958575 | 0.86 | P2RX7 (0.58) | P2RX7P2RX3 | |
| SCHEMBL13958610 | 0.85 | P2RX7 (0.59) | P2RX7P2RX3 | |
| SCHEMBL13958600 | 0.84 | P2RX7 (0.56) | P2RX7P2RX3 | |
| SCHEMBL13958623 | 0.81 | P2RX7 (0.53) | P2RX7P2RX3 | |
| SCHEMBL13958603 | 0.80 | P2RX7 (0.55) | P2RX7P2RX3 | |
| SCHEMBL13958562 | 0.80 | P2RX7 (0.75) | P2RX7P2RX3 | |
| SCHEMBL13958573 | 0.79 | P2RX7 (0.60) | P2RX7P2RX3 | |
| SCHEMBL13958590 | 0.79 | P2RX7 (0.60) | P2RX7P2RX3 | |
| SCHEMBL13958566 | 0.79 | P2RX7 (0.61) | P2RX7P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018133-A1 | Novel Adamantane Derivatives | FORD RHONAN | 2009-01-15 | — | — | US | disclosed |
| US-20090018133-A1 | Novel Adamantane Derivatives | FORD RHONAN | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018133-A1 | Novel Adamantane Derivatives | ADRA1A, ADORA1, ADRA1D | P2RX7 554/4885HPGD 1933/4885KDM4E 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.